Cargando…

Diagnostic approach in adult-onset neurometabolic diseases

Neurometabolic diseases are a group of individually rare but numerous and heterogeneous genetic diseases best known to paediatricians. The more recently reported adult forms may present with phenotypes strikingly different from paediatric ones and may mimic other more common neurological disorders i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Eulate, Gorka, Carreau, Christophe, Benoist, Jean-François, Lamari, Foudil, Rucheton, Benoit, Shor, Natalia, Nadjar, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921565/
https://www.ncbi.nlm.nih.gov/pubmed/35140137
http://dx.doi.org/10.1136/jnnp-2021-328045
_version_ 1784669350402195456
author Fernández-Eulate, Gorka
Carreau, Christophe
Benoist, Jean-François
Lamari, Foudil
Rucheton, Benoit
Shor, Natalia
Nadjar, Yann
author_facet Fernández-Eulate, Gorka
Carreau, Christophe
Benoist, Jean-François
Lamari, Foudil
Rucheton, Benoit
Shor, Natalia
Nadjar, Yann
author_sort Fernández-Eulate, Gorka
collection PubMed
description Neurometabolic diseases are a group of individually rare but numerous and heterogeneous genetic diseases best known to paediatricians. The more recently reported adult forms may present with phenotypes strikingly different from paediatric ones and may mimic other more common neurological disorders in adults. Furthermore, unlike most neurogenetic diseases, many neurometabolic diseases are treatable, with both conservative and more recent innovative therapeutics. However, the phenotypical complexity of this group of diseases and the growing number of specialised biochemical tools account for a significant diagnostic delay and underdiagnosis. We reviewed all series and case reports of patients with a confirmed neurometabolic disease and a neurological onset after the age of 10 years, with a focus on the 36 treatable ones, and classified these diseases according to their most relevant clinical manifestations. The biochemical diagnostic approach of neurometabolic diseases lays on the use of numerous tests studying a set of metabolites, an enzymatic activity or the function of a given pathway; and therapeutic options aim to restore the enzyme activity or metabolic function, limit the accumulation of toxic substrates or substitute the deficient products. A quick diagnosis of a treatable neurometabolic disease can have a major impact on patients, leading to the stabilisation of the disease and cease of repeated diagnostic investigations, and allowing for familial screening. For the aforementioned, in addition to an exhaustive and clinically meaningful review of these diseases, we propose a simplified diagnostic approach for the neurologist with the aim to help determine when to suspect a neurometabolic disease and how to proceed in a rational manner. We also discuss the place of next-generation sequencing technologies in the diagnostic process, for which deep phenotyping of patients (both clinical and biochemical) is necessary for improving their diagnostic yield.
format Online
Article
Text
id pubmed-8921565
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89215652022-03-25 Diagnostic approach in adult-onset neurometabolic diseases Fernández-Eulate, Gorka Carreau, Christophe Benoist, Jean-François Lamari, Foudil Rucheton, Benoit Shor, Natalia Nadjar, Yann J Neurol Neurosurg Psychiatry Neurogenetics Neurometabolic diseases are a group of individually rare but numerous and heterogeneous genetic diseases best known to paediatricians. The more recently reported adult forms may present with phenotypes strikingly different from paediatric ones and may mimic other more common neurological disorders in adults. Furthermore, unlike most neurogenetic diseases, many neurometabolic diseases are treatable, with both conservative and more recent innovative therapeutics. However, the phenotypical complexity of this group of diseases and the growing number of specialised biochemical tools account for a significant diagnostic delay and underdiagnosis. We reviewed all series and case reports of patients with a confirmed neurometabolic disease and a neurological onset after the age of 10 years, with a focus on the 36 treatable ones, and classified these diseases according to their most relevant clinical manifestations. The biochemical diagnostic approach of neurometabolic diseases lays on the use of numerous tests studying a set of metabolites, an enzymatic activity or the function of a given pathway; and therapeutic options aim to restore the enzyme activity or metabolic function, limit the accumulation of toxic substrates or substitute the deficient products. A quick diagnosis of a treatable neurometabolic disease can have a major impact on patients, leading to the stabilisation of the disease and cease of repeated diagnostic investigations, and allowing for familial screening. For the aforementioned, in addition to an exhaustive and clinically meaningful review of these diseases, we propose a simplified diagnostic approach for the neurologist with the aim to help determine when to suspect a neurometabolic disease and how to proceed in a rational manner. We also discuss the place of next-generation sequencing technologies in the diagnostic process, for which deep phenotyping of patients (both clinical and biochemical) is necessary for improving their diagnostic yield. BMJ Publishing Group 2022-04 2022-02-09 /pmc/articles/PMC8921565/ /pubmed/35140137 http://dx.doi.org/10.1136/jnnp-2021-328045 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neurogenetics
Fernández-Eulate, Gorka
Carreau, Christophe
Benoist, Jean-François
Lamari, Foudil
Rucheton, Benoit
Shor, Natalia
Nadjar, Yann
Diagnostic approach in adult-onset neurometabolic diseases
title Diagnostic approach in adult-onset neurometabolic diseases
title_full Diagnostic approach in adult-onset neurometabolic diseases
title_fullStr Diagnostic approach in adult-onset neurometabolic diseases
title_full_unstemmed Diagnostic approach in adult-onset neurometabolic diseases
title_short Diagnostic approach in adult-onset neurometabolic diseases
title_sort diagnostic approach in adult-onset neurometabolic diseases
topic Neurogenetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921565/
https://www.ncbi.nlm.nih.gov/pubmed/35140137
http://dx.doi.org/10.1136/jnnp-2021-328045
work_keys_str_mv AT fernandezeulategorka diagnosticapproachinadultonsetneurometabolicdiseases
AT carreauchristophe diagnosticapproachinadultonsetneurometabolicdiseases
AT benoistjeanfrancois diagnosticapproachinadultonsetneurometabolicdiseases
AT lamarifoudil diagnosticapproachinadultonsetneurometabolicdiseases
AT ruchetonbenoit diagnosticapproachinadultonsetneurometabolicdiseases
AT shornatalia diagnosticapproachinadultonsetneurometabolicdiseases
AT nadjaryann diagnosticapproachinadultonsetneurometabolicdiseases